ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Evaluation of an Intimate Partner Violence Screening-Intervention

This study has been suspended.

Sponsors and Collaborators: University at Albany
Johns Hopkins University
Information provided by: University at Albany
ClinicalTrials.gov Identifier: NCT00257296
  Purpose

The purpose of the study is to evaluate a multi-faceted intimate partner violence (IPV) screening/intervention targeting abused women who are seen for prenatal care in obstetrics-gynecology clinics or general medical care in internal medicine clinics. The intervention is based on our clinical experience and review of the literature which suggests: 1) IPV can vary and no one pattern exists for all women; 2) recovery from abuse usually occurs over time and not necessarily immediately after it is first detected; 3) women have gone down many different paths leading to an abusive relationship and there is no single path to recovery; 4) for screening/interventions to be credible and ultimately disseminated they must respond to the complexity of the patient stories clinicians see everyday when caring for women experiencing IPV and 5) busy obstetricians/internists/clinicians are unlikely to effectively screen and treat women experiencing IPV unless they are supported by other personnel trained to address IPV as well.

The intervention also is based on recommendations of IPV experts and on the theory of chronic disease management that recognizes that the best outcomes are achieved when: 1) patients are educated and given the support and skills to set their own goals and make their own choices; 2) multidisciplinary teams work better than programs focused only on physician behavior; 3) active monitoring of progress is essential; 4) active coping styles using a range of therapeutic modalities are available and 5) a stepped approach is utilized with those not making progress or with more severe problems receiving the greatest intensity of services.

The screening/intervention will be available to each abused woman for approximately three to six months. Patients in the evaluation study will be surveyed at the following time points: baseline, 1 week, 1 month, 3 months, 6 months, and for the partial cohort that starts early, 9 months. Additionally, a sample of nonabused women will be surveyed at baseline to serve as a referent group.

Our primary hypotheses are, that compared to usual care, abused women receiving the intervention will have a reduction in levels of IPV, decreases in depression and nonspecific physical symptoms, increase in functional health status, increase in safety behaviors, increase in help seeking for issues related to IPV, and reduction of general medical services.


Condition Intervention
Domestic Violence
Procedure: Screening Protocol for Intimate Partner Violence
Procedure: Intervention Protocol for Intimate Partner Violence

MedlinePlus related topics:   Domestic Violence   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Randomized, Open Label, Active Control, Parallel Assignment
Official Title:   Evaluation of an Intimate Partner Violence Screening-Intervention

Further study details as provided by University at Albany:

Estimated Enrollment:   2000

  Eligibility
Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female

Criteria

Inclusion Criteria:

Females Ages 18 to 45 years Seen at study sites for primary care during study periods Speaks English Able to separate from accompanying person(s) Willing to participant

Exclusion Criteria:

Too ill to participate Unable to separate from accompanying person(s) Unable to speak English Refuse to participant

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257296

Sponsors and Collaborators
University at Albany
Johns Hopkins University

Investigators
Principal Investigator:     Louise-Anne McNutt, PhD     University at Albany, State University of New York    
Principal Investigator:     Daniel Ford, MD, MS     Johns Hopkins University    
  More Information


Study ID Numbers:   S1751
First Received:   November 21, 2005
Last Updated:   November 21, 2005
ClinicalTrials.gov Identifier:   NCT00257296
Health Authority:   United States: Institutional Review Board

ClinicalTrials.gov processed this record on September 19, 2008




Links to all studies - primarily for crawlers